More Unnecessary Imaginary Worlds – Part 4: The ICER Evidence Report for Crizanlizumab, Voxelotor and L-Glutamine for Sickle Cell Disease

A number of commentaries have been published over the past 4 years by the present author on the manifest flaws in the reference case value assessment framework of the Institute for Economic and Clinical Review. The recent release of the evidence report on sickle cell disease continues ICER’s commit...

Full description

Bibliographic Details
Main Author: Paul Langley
Format: Article
Language:English
Published: University of Minnesota Libraries Publishing 2020-05-01
Series:INNOVATIONS in Pharmacy
Subjects:
Online Access:https://pubs.lib.umn.edu/index.php/innovations/article/view/3123